Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers

Author:

Resong Paul J.12ORCID,Niu Jiangong1ORCID,Duhon Gabrielle F.1ORCID,Foxhall Lewis E.3ORCID,Shete Sanjay45ORCID,Volk Robert J.1ORCID,Toumazis Iakovos1ORCID

Affiliation:

1. 1Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.

2. 2University of Nevada, Reno School of Medicine, Reno, Nevada.

3. 3Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, Texas.

4. 4Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.

5. 5Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, Texas.

Abstract

Abstract Current lung cancer screening (LCS) guidelines rely on age and smoking history. Despite its benefit, only 5%–15% of eligible patients receive LCS. Personalized screening strategies select individuals based on their lung cancer risk and may increase LCS's effectiveness. We assess current LCS practices and the acceptability of personalized LCS among primary care providers (PCP) in Texas. We surveyed 32,983 Texas-based PCPs on an existing network (Protocol 2019-1257; PI: Dr. Shete) and 300 attendees of the 2022 Texas Academy of Family Physicians (TAFP) conference. We analyzed the responses by subgroups of interest. Using nonparametric bootstrap, we derived an enriched dataset to develop logistic regression models to understand current LCS practices and acceptability of personalized LCS. Response rates were 0.3% (n = 91) and 15% (n = 60) for the 2019–1257 and TAFP surveys, respectively. Most (84%) respondents regularly assess LCS in their practice. Half of the respondents were interested in adopting personalized LCS. The majority (66%) of respondents expressed concerns regarding time availability with the personalized LCS. Most respondents would use biomarkers as an adjunct to assess eligibility (58%), or to help guide indeterminate clinical findings (63%). There is a need to enhance the engagement of Texas-based PCPs in LCS. Most of the respondents expressed interest in personalized LCS. Time availability was the main concern related to personalized LCS. Findings from this project highlight the need for better education of Texas-based PCPs on the benefits of LCS, and the development of efficient decision tools to ensure successful implementation of personalized LCS. Prevention Relevance: Personalized LCS facilitated by a risk model and/or a biomarker test is proposed as an alternative to existing programs. Acceptability of personalized approach among PCPs is unknown. The goal of this study is to assess the acceptability of personalized LCS among PCPs.

Funder

National Cancer Institute

Cancer Prevention and Research Institute of Texas

Publisher

American Association for Cancer Research (AACR)

Reference27 articles.

1. Annual report to the nation on the status of cancer, part 1: National Cancer Statistics;Cronin;Cancer,2022

2. Screening for lung cancer: US preventive services task force recommendation statement;US Preventive Services Task Force;JAMA,2021

3. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement;Moyer;Ann Intern Med,2014

4. Reduced lung-cancer mortality with low-dose computed tomographic screening;Aberle;N Engl J Med,2011

5. Reduced lung-cancer mortality with volume CT screening in a randomized trial;de Koning;N Engl J Med,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3